NIH Launches Trial to Evaluate Long-acting HIV Medication in People Unable to Adhere to Strict Daily Regimens

May 20, 2019 | Kim Rodgers

The National Institutes of Health has launched the Long-Acting Therapy to Improve Treatment Success in Daily Life (LATITUDE) study, which compares monthly injectable antiretroviral therapy to daily oral drugs in people unable to adhere to strict daily regimens. The trial is funded by the National Institute of Allergy and Infectious and will be conducted by the AIDS Clinical Trials Group with support from the National Institute of Mental Health, the National Institute on Drug Abuse, ViiV Healthcare, and the Janssen Pharmaceutical Companies of Johnson & Johnson.

The trial will evaluate two experimental, long-acting injections of the antiretroviral drugs rilpivirine and cabotegravir, which will be administered every four weeks by a healthcare professional in a research clinic. Throughout the study, investigators will evaluate volunteers’ viral load—the measure of virus in the blood—and other indicators of immune health to compare the treatment’s effectiveness to that of conventional oral ART.

Learn more about the study.


637020799465370000

About Kim Rodgers

Kim Rodgers is the Communications Manager at NACCHO.

More posts by Kim Rodgers

0 Comments

Related Posts

Cdc badge small
  • Tools & Resources

CDC Report: Temporary Reassignment of Personnel Requests...

CDC recently updated its flexibilities guidance for recipients and applicants...

Jul 09, 2020 | Kim Rodgers

CDC Report: Temporary Reassignment of Personnel Requests...

Jennifer kertanis headshot 24152456360
  • Opportunity

Top Moments From Day Two at NACCHO 360

Welcome to the final day of NACCHO 360! Yesterday NACCHO Chief Executive...

Jul 09, 2020 | Taylarr Lopez

Top Moments From Day Two at NACCHO 360

COVID VC Screenshot
  • COVID-19
  • Tools & Resources
  • Emergency Response
  • Infectious Disease

NACCHO’s COVID-19 Virtual Community Now Available to All...

NACCHO has opened our COVID-19 Virtual Community to all local health department...

Jul 08, 2020 | Kim Rodgers

NACCHO’s COVID-19 Virtual Community Now Available to All...

Sync2020 logos horizontal 1024x304
  • HIV, STI, & Viral Hepatitis

Scholarships Available: SYNChronicity 2020 Conference –...

SYNC 2020, the National Conference for HIV, HCV, STI and LGBTQ Health, is...

Jul 08, 2020 | Julia Zigman

Scholarships Available: SYNChronicity 2020 Conference –...

  • COVID-19
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Kaiser Family Foundation: Reduction in Sexual and...

The Kaiser Family Foundation released a new issue brief, Potential Impacts of...

Jul 08, 2020 | Julia Zigman

Kaiser Family Foundation: Reduction in Sexual and...

2000px US CDC logo
  • HIV, STI, & Viral Hepatitis

New Recommendations for Hepatitis Vaccination

CDC has released new recommendations for hepatitis A virus (HAV) vaccination,...

Jul 08, 2020 | Julia Zigman

New Recommendations for Hepatitis Vaccination

TAG Logo
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Treatment Action Group 2020 Pipeline Report Now Available

Treatment Action Group (TAG) recently published their 2020 Pipeline Report, an...

Jul 08, 2020 | Julia Zigman

Treatment Action Group 2020 Pipeline Report Now Available

Pr EP injectable
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

New Study: Injectable PrEP is Safe and Highly Effective

New data further shows an injectable antiretroviral for HIV pre-exposure...

Jul 08, 2020 | Julia Zigman

New Study: Injectable PrEP is Safe and Highly Effective

MMWR
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

HIV Testing Trends at Visits to Physician Offices,...

A recent report from CDC shows low rates of HIV testing in physician offices,...

Jul 08, 2020 | Julia Zigman

HIV Testing Trends at Visits to Physician Offices,...

Back to Top